Business Description
Maccura Biotechnology Co Ltd
ISIN : CNE1000020H3
Share Class Description:
SZSE:300463: Class ACompare
Compare
Traded in other countries / regions
300463.China IPO Date
2015-05-28Description
Maccura Biotechnology Co Ltd is a China-based in-vitro diagnostic (IVD) integration company engaged in the research and development, production and sales of IVD products. It is also engaged in the sales of foreign brands of in vitro diagnostic products as an agent. The company's developed product and technology development platforms cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.46 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | 1.82 | |||||
| Interest Coverage | 17.75 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.38 | |||||
| Beneish M-Score | -2.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.9 | |||||
| 3-Year EBITDA Growth Rate | 3.1 | |||||
| 3-Year EPS without NRI Growth Rate | 7.8 | |||||
| 3-Year FCF Growth Rate | -43.2 | |||||
| 3-Year Book Growth Rate | 22.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.28 | |||||
| 9-Day RSI | 35.92 | |||||
| 14-Day RSI | 38.35 | |||||
| 6-1 Month Momentum % | -7.23 | |||||
| 12-1 Month Momentum % | -25.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.71 | |||||
| Quick Ratio | 2.8 | |||||
| Cash Ratio | 0.98 | |||||
| Days Inventory | 295 | |||||
| Days Sales Outstanding | 232.83 | |||||
| Days Payable | 107.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.95 | |||||
| Dividend Payout Ratio | 0.46 | |||||
| 3-Year Dividend Growth Rate | 43.3 | |||||
| Forward Dividend Yield % | 2.95 | |||||
| 5-Year Yield-on-Cost % | 13.83 | |||||
| 3-Year Average Share Buyback Ratio | -3.2 | |||||
| Shareholder Yield % | 4.61 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.02 | |||||
| Operating Margin % | 18.95 | |||||
| Net Margin % | 12.51 | |||||
| FCF Margin % | -5.8 | |||||
| ROE % | 5.98 | |||||
| ROA % | 4.58 | |||||
| ROIC % | 8 | |||||
| ROC (Joel Greenblatt) % | 8.55 | |||||
| ROCE % | 6.26 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.02 | |||||
| PE Ratio without NRI | 15.51 | |||||
| Shiller PE Ratio | 10.6 | |||||
| PEG Ratio | 1.08 | |||||
| PS Ratio | 2.34 | |||||
| PB Ratio | 1.13 | |||||
| Price-to-Tangible-Book | 1.24 | |||||
| Price-to-Operating-Cash-Flow | 8.26 | |||||
| EV-to-EBIT | 15.35 | |||||
| EV-to-EBITDA | 15.35 | |||||
| EV-to-Revenue | 2.28 | |||||
| EV-to-FCF | -41.06 | |||||
| Price-to-Projected-FCF | 1.09 | |||||
| Price-to-DCF (Earnings Based) | 0.67 | |||||
| Price-to-Graham-Number | 0.92 | |||||
| Price-to-Net-Current-Asset-Value | 2.77 | |||||
| Earnings Yield (Greenblatt) % | 6.51 | |||||
| FCF Yield % | -2.44 | |||||
| Forward Rate of Return (Yacktman) % | 3.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Maccura Biotechnology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,005.201 | ||
| EPS (TTM) (Â¥) | 0.613 | ||
| Beta | 0.97 | ||
| Volatility % | 28.62 | ||
| 14-Day RSI | 38.35 | ||
| 14-Day ATR (Â¥) | 0.435478 | ||
| 20-Day SMA (Â¥) | 12.627 | ||
| 12-1 Month Momentum % | -25.52 | ||
| 52-Week Range (Â¥) | 9.9 - 18.18 | ||
| Shares Outstanding (Mil) | 612.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Maccura Biotechnology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Maccura Biotechnology Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Maccura Biotechnology Co Ltd Frequently Asked Questions
What is Maccura Biotechnology Co Ltd(SZSE:300463)'s stock price today?
The current price of SZSE:300463 is ¥11.66. The 52 week high of SZSE:300463 is ¥18.18 and 52 week low is ¥9.90.
When is next earnings date of Maccura Biotechnology Co Ltd(SZSE:300463)?
The next earnings date of Maccura Biotechnology Co Ltd(SZSE:300463) is .
Does Maccura Biotechnology Co Ltd(SZSE:300463) pay dividends? If so, how much?
The Dividend Yield %  of Maccura Biotechnology Co Ltd(SZSE:300463) is 2.95% (As of Today), Highest Dividend Payout Ratio of Maccura Biotechnology Co Ltd(SZSE:300463) was 0.46. The lowest was 0.14. And the median was 0.17. The  Forward Dividend Yield % of Maccura Biotechnology Co Ltd(SZSE:300463) is 2.95%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers